Getting the balance right: Established and emerging therapies for major depressive disorders
Article (Published version)
Metadata
Show full item recordAbstract
Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, ...compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.
Keywords:
major depressive disorders / monoamine deficiency / antidepressants / depressionSource:
Neuropsychiatric Disease and Treatment, 2010, 6, 343-364Publisher:
- Dove Medical Press Ltd, Albany
Funding / projects:
- Eksperimentalna i kliničko-farmakološka istraživanja mehanizma dejstva i interakcija lekova u nervnom i kardiovaskularnom sistemu (RS-MESTD-MPN2006-2010-145001)
Collections
Institution/Community
PharmacyTY - JOUR AU - Perović, Bojana AU - Jovanović, Marija AU - Miljković, Branislava AU - Vezmar, Sandra PY - 2010 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1392 AB - Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising. PB - Dove Medical Press Ltd, Albany T2 - Neuropsychiatric Disease and Treatment T1 - Getting the balance right: Established and emerging therapies for major depressive disorders VL - 6 SP - 343 EP - 364 DO - 10.2147/NDT.S10485 UR - https://hdl.handle.net/21.15107/rcub_farfar_1392 ER -
@article{ author = "Perović, Bojana and Jovanović, Marija and Miljković, Branislava and Vezmar, Sandra", year = "2010", abstract = "Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.", publisher = "Dove Medical Press Ltd, Albany", journal = "Neuropsychiatric Disease and Treatment", title = "Getting the balance right: Established and emerging therapies for major depressive disorders", volume = "6", pages = "343-364", doi = "10.2147/NDT.S10485", url = "https://hdl.handle.net/21.15107/rcub_farfar_1392" }
Perović, B., Jovanović, M., Miljković, B.,& Vezmar, S.. (2010). Getting the balance right: Established and emerging therapies for major depressive disorders. in Neuropsychiatric Disease and Treatment Dove Medical Press Ltd, Albany., 6, 343-364. https://doi.org/10.2147/NDT.S10485 https://hdl.handle.net/21.15107/rcub_farfar_1392
Perović B, Jovanović M, Miljković B, Vezmar S. Getting the balance right: Established and emerging therapies for major depressive disorders. in Neuropsychiatric Disease and Treatment. 2010;6:343-364. doi:10.2147/NDT.S10485 https://hdl.handle.net/21.15107/rcub_farfar_1392 .
Perović, Bojana, Jovanović, Marija, Miljković, Branislava, Vezmar, Sandra, "Getting the balance right: Established and emerging therapies for major depressive disorders" in Neuropsychiatric Disease and Treatment, 6 (2010):343-364, https://doi.org/10.2147/NDT.S10485 ., https://hdl.handle.net/21.15107/rcub_farfar_1392 .